International Journal of Cardiology
Volume 131, Issue 2 , Pages 204-211 , 9 January 2009

Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation

  • L.M. Dijksman

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • A. Hirsch

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • F. Windhausen

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • F.F. Asselman

      Affiliations

    • Economic Department, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • J.G.P. Tijssen

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • M.G.W. Dijkgraaf

      Affiliations

    • Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, Amsterdam, The Netherlands
    • ,
  • R.J. de Winter

      Affiliations

    • Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Department of Cardiology, B2-137, Academic Medical Centre, Meibergdreef 9, PO Box 22660, 1100 DD Amsterdam, The Netherlands. Tel.: +31 20 5669111; fax: +31 20 6962609.
    • ,
  • for the Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators

Received 26 January 2007 ,Revised 21 August 2007 ,Accepted 20 October 2007.

References 

  1. Boden WE, McKay RG. Optimal treatment of acute coronary syndromes—an evolving strategy. N Engl J Med. 2001;344:1939–1942
  2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366–1374
  3. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293:2908–2917
  4. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545–1556
  5. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. 1999;354:708–715
  6. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. 1998;338:1785–1792
  7. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879–1887
  8. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet. 2002;360:743–751
  9. Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J. 2002;23:31–40
  10. Mahoney EM, Jurkovitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851–1858
  11. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. 2005;353:1095–1104
  12. Oostenbrink JB, Koopmanschap MA, Rutten FF. Guidelines for cost calculations, methods and recommended prices for economic evaluations in health care [in Dutch]. Amstelveen: College voor Zorgverzekeringen; 2000;
  13. Central Medical Pharmaceutical Committee of the National Health Service Council . Farmaceutisch Kompas. Utrecht: National Health Service Council; 2005;
  14. Briggs AH, O'Brien BJ. The death of cost-minimization analysis?. Health Econ. 2001;10:179–184
  15. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19:3219–3236
  16. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Third Edition. New York: Oxford University Press; 2005;
  17. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 2004;13:405–415
  18. Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504

PII: S0167-5273(07)01947-X

doi: 10.1016/j.ijcard.2007.10.019

International Journal of Cardiology
Volume 131, Issue 2 , Pages 204-211 , 9 January 2009

Article Tools

* Image Usage & Resolution